Suven Life Sciences Q2 FY26 results: wider losses on higher R&D spend

Revenue DeclinePat NegativeNegative Operating CashflowEbitda Margin CompressionResults View source PDF Explain this filing

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.5%Reaction day

₹187.25

prior close

₹181.47

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.3%-2.3% vs market

Healthcare Services peers, median of 51sector · industry level-0.6%-2.0% vs sector

On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 2.0 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.6

15m

+1.0

30m

+0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.5-0.3-2.3-0.6-2.0

Next day

+0.1+0.7-0.5+0.1+0.1

-2.4+0.6-3.0+1.6-3.9

-0.6+0.5-1.1+0.2-0.8

-3.1+1.1-4.2+1.0-4.1

-4.4+0.3-4.6-1.3-3.1

-5.6-0.2-5.4-0.4-5.3

15d

-8.0-2.2-5.8-1.3-6.7

-10.3-4.9-5.4-3.1-7.2

-18.6-7.5-11.2-5.3-13.3

-16.3-4.8-11.6-9.0-7.3

UpDownMarket · Nifty Microcap 250Sector · Healthcare Services peers, median of 51Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Suven Life Sciences Q2 FY26: standalone net loss widened to Rs. 15.45 crore (vs Rs. 11.07 crore YoY). Consolidated net loss was Rs. 77.31 crore (vs Rs. 49.64 crore YoY) as R&D spend rose to Rs. 70.32 crore from Rs. 47.58 crore. Revenue from operations fell sharply to Rs. 91.92 lakh from Rs. 2.57 crore YoY. Company raised Rs. 306.73 crore via preferential warrants, used Rs. 54.24 crore so far.

Likely market impact

Heavy R&D spending keeps the company in losses. Cash from a Rs. 306.73 crore warrant raise funds clinical trials through fiscal 2026.